CN1679970A - Preparation of radiative immune guiding operating medicine of colorectal disease - Google Patents
Preparation of radiative immune guiding operating medicine of colorectal disease Download PDFInfo
- Publication number
- CN1679970A CN1679970A CN 200510011277 CN200510011277A CN1679970A CN 1679970 A CN1679970 A CN 1679970A CN 200510011277 CN200510011277 CN 200510011277 CN 200510011277 A CN200510011277 A CN 200510011277A CN 1679970 A CN1679970 A CN 1679970A
- Authority
- CN
- China
- Prior art keywords
- antibody
- preparation
- labelling
- medicine
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A medicine for the radioimmunoguide operation of colon cancer and rectum cancer is prepared from antibody CL58 through making and freeze drying. It features its clinic application at any time.
Description
Technical field
The present invention relates to a kind of preparation method of radioimmunoguided surgery system medicine, specifically, the present invention relates to a kind of preparation method of radiative immune guiding operating medicine of colorectal disease.
Background technology
50% colorectal cancer patients of accepting radical surgery finally can recur, and wherein main cause is indiscoverable micrometastasis kitchen range.Radioimmunoguided surgery system (RIGS, RadioImmunoGuided Surgery) provides standard qualitatively for the judgement that solves micrometastasis kitchen range on the operating-table, and excision micrometastasis kitchen range provides reliable means in order to perform the operation thoroughly.
RIGS is that (RII RadioImmunImaging) on the basis of level diagnosis, uses the technology of surveying tumor and metastatic lymph node thereof in the hand-held detector art at radio-immuno-image.In the RIGS of colorectal cancer uses, adopt monoclonal antibody such as the B72.3 and the CC49 of hybridoma technology preparation at present more.The radioactive label nucleic that uses is
111In and
125I and
131I etc.
When at present the antibody of the radioisotope labeling that the uses RIGS medicine that carries out colorectal cancer is interim use, temporary marker.This exists very big clinical use inconvenience.It comprises the predetermined of radionuclide, if also needing to wait, import goes up 2-4 week, be unfavorable in time the operation to patient fully, radiopharmaceutic labelling is subjected to time, labelling place and radiopharmaceutical operator's restriction simultaneously, influences carrying out and applying of RIGS greatly.Develop a kind ofly can preserve, can satisfy clinical instructions for use at any time the long period, be not subjected to the restriction of labelling place, patient with to use at any time, the flexible medicine that is used for colorectal cancer RIGS will carry out RIGS to the clinician and bring great convenience, can the very first time carry out administration simultaneously and also in time undergo surgery to the patient.
Summary of the invention
Goal of the invention of the present invention is to provide the preparation method of the radiative immune guiding operating medicine of colorectal disease that uses at any time.
For achieving the above object, the invention provides a kind of radiative immune guiding operating medicine of colorectal disease, it is characterized in that, described medicine is to be made after labelling, lyophilizing by CL58 antibody.
The present invention also provides a kind of manufacturing method for above mentioned medicine, it is characterized in that, this method may further comprise the steps:
(1) radioactive labelling: in CL58 antibody, add buffer solution adjust pH to 7.4, after shaking up, add Na
125I solution adds N-bromosuccinimide again, shakes up, and fully after the reaction, adds human serum albumin's cessation reaction, and uses the PD-10 column purification, obtains the antibody behind the labelling purification;
(2) purification of traget antibody: before labelling, get one on the PD-10 post that Sigma company produces, with this post of the saturated drip washing of phosphate buffer solution 25ml of the 0.01M of pH7.2, and with the saturated pillar of the human serum albumin of 10mg, stand-by then.Column purification on the antibody behind the labelling, volume is no more than 2.5ml, supply with the phosphate buffer solution of the 0.01M of pH7.2 the back of going up of not enough 2.5ml, this 2.5ml leacheate of the collection of abandoning, and then with the phosphate buffer solution drip washing of the 0.01M of the pH7.2 of 2.5ml, collect this leacheate 2.5ml, be the product of final labelling.
(3) lyophilizing of traget antibody: get the antibody behind the labelling purification, add protective agent, forming agent or polysaccharide postlyophilization and get final product.
Wherein said buffer solution is phosphate buffer; Described protective agent is selected from following material: human serum albumin, V
C, human IgG and other irrelevant protein; Described forming agent is selected from following material: carbamide, sucrose, fructose etc.; Described polysaccharide is selected from one or more in the following material: mannitol, sucrose, fructose etc.
The maximum characteristics of this medicine are clinical can the uses at any time, avoided former preparation guiding operating medicine be subjected to flag condition, radiosiotope source and labelling environment etc. the restriction of condition, overcome the shortcoming that is subjected to the radiopharmaceutical restriction in the guiding operating popularization process.
Description of drawings
Fig. 1 is that the T/NT ratio of lotus human colon carcinoma CL187 nude mice is schemed over time behind the injection 125I-CL58.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.
Embodiment 1:
Radioactive labelling: get CL58 antibody 1.0mg (5.0mg/ml) and add 0.1mlpH7.4 phosphate buffer solution (PB), after shaking up, add 185MBq Na
125I solution adds the NBS of 12-16 μ g then, shakes gently, and reaction adds the HSA cessation reaction of 20mg to the suitable time.Measure mark rate, and use the PD10 column purification.
The lyophilizing of traget antibody: get the antibody behind the labelling purification, the specific activity of its traget antibody is 3mCi/mg, and antibody concentration is 0.6mCi/ml, adds protective agent human serum albumin (HSA), and HSA content is 4mg/ml and an amount of mannitol.Divide to install in the clean cillin bottle, every bottle of 0.5ml adopts Dura-Dry
TMThe freeze dryer lyophilization, lyophilizing is finished behind the 24h.Measure the polymerization situation of dissolubility, antibody activity and the antibody of freeze dried traget antibody then, and place the iodine rate of taking off and the activity change of traget antibody behind the different time and carry out the SDS-PAGE electrophoretic analysis.
Sample after the lyophilizing becomes white block, shakes into fluffy Powdered gently.Dissolved in distilled water with 0.5ml becomes flaxen clear solution (yellow is thought of as the color of HSA), and pH is about 7.2.Free-iodine content is about 8% (n=10) behind the placement 30d.
Embodiment 2:
(1) radioactive labelling: in CL58 antibody, add phosphate buffer solution adjust pH to 7.2, after shaking up, add 111MBqNa
125I solution adds 14 μ gN-bromo-succinimide again, shakes up, and fully after the reaction, adds human serum albumin's cessation reaction, and obtains antibody behind the labelling purification with the PD10 column purification;
(2) lyophilizing of traget antibody: get the antibody behind the labelling purification, add human serum albumin's postlyophilization and get final product.
Experimental example 1:
Research distributes in the animal body of freeze dried traget antibody: after the sample after the lyophilizing is used the 0.5ml dissolved in distilled water, with aseptic pH7.2 phosphate buffer solution dilution, give the freeze dried traget antibody of lotus CL-187 human colon carcinoma nude mice tail vein injection then
125I-CL58, volume injected 0.1ml, radioactivity is 370KBq, antibody content is 3.3 μ g.Simultaneously drink 1% KI water to nude mice with the sealing thyroid preceding 3 days of medication.Get blood (5 every group) in injection back 1d, 3d, 5d and 7d etc. from eyeball, twist off cervical vertebra till death, dissect, core, liver,spleen,kidney, lung, stomach, intestinal, muscle, skeleton and tumor, weigh, and measure radiocounting, calculate ID%/g and T/NT ratio.Distribution results sees Table 1 in the concrete body.
From table 1 we as can be seen: the injection freeze dried traget antibody after the 24h tumor uptake just than the radioactive uptake height other each organs and tissues, T/NT is all greater than 1.Reach the highest at 72 hours tumor uptakes in injection behind the 125I-CL58, ID%/g is up to being 14.7%.The 7d tumor uptake is still up to 11.5% after the medication, and T/NT is all greater than 3.0 above (see figure 1)s.This shows that the labelling sample after the lyophilizing has kept very high biological activity, and the lyophilizing sample has good tumor-targeting.Along with the prolongation of time, T/NT is more and more higher.
Mice with tumor video picture: get lotus people colon-cancer cell CL187 nude mice, when the about 0.5cm of tumor diameter, preceding 3 days of medication is given and is drunk 1% KI water with the sealing thyroid, tail vein injection traget antibody 0.1ml then, radioactivity is about 0.1mCi, under the ECT of Siemens ICON, carry out image acquisition in injection back 1d, 2d, 3d, 4d and 7d, can the peak be that 51keV is (because of the low-energy peak of instrument is 51keV, can window be 80%, acquisition matrix is 128 * 128, zoom is 3.20, carries out the video picture of nude mice normotopia, observes tumor uptake and changes and the whole body distribution situation.Its video picture the results are shown in Figure 2 (arrow is depicted as tumor), as seen from the figure, inject 24h behind the freeze dried traget antibody, the just clear video picture of energy of tumor, As time goes on, tumor imaging is more and more clear, almost just has only tumor imaging behind 7d, show that the traget antibody after the lyophilizing has good biological activity tumor-targeting, the RIGS that carries out intestinal cancer for this freeze-dried drug provides strong medicine support.
Table 1.
125(lotus CL187 intestinal cancer distributes in the animal body of the anti-CEA monoclonal antibody CL58 of I labelling
The cell nude mice, N=5)
| ?ORGAN | ????24h | ????48h | ????72h | ????168h |
| Blood | ??9.32±1.16 | ??7.45±1.14 | ??5.6±1.34 | ??3.39±0.13 |
| The heart | ??2.52±0.27 | ??1.85±0.42 | ??1.42±0.26 | ??0.89±0.12 |
| Liver | ??2.73±0.25 | ??2.40±0.72 | ??1.24±0.24 | ??0.96±0.21 |
| Spleen | ??2.56±0.23 | ??2.79±1.22 | ??1.11±0.28 | ??0.92±0.19 |
| Kidney | ??2.44±0.40 | ??1.74±0.19 | ??1.26±0.07 | ??0.84±0.05 |
| Lung | ??3.63±0.54 | ??3.24±0.99 | ??2.39±1.02 | ??1.67±0.13 |
| Stomach | ??1.23±0.31 | ??0.92±0.24 | ??0.66±0.10 | ??0.43±0.05 |
| Intestinal | ??1.16±0.11 | ??0.77±0.36 | ??0.63±0.11 | ??0.38±0.04 |
| Muscle | ??0.61±0.11 | ??0.79±0.45 | ??0.45±0.09 | ??0.28±0.02 |
| Bone | ??1.25±0.18 | ??1.23±0.34 | ??0.68±0.20 | ??0.50±0.04 |
| Tumor | ??10.38±5.4 | ??14.01±3.11 | ??14.70±2.10 | ??11.56±0.90 |
The T/NT ratio of lotus human colon carcinoma CL187 nude mice is seen Fig. 1 over time behind the injection 125I-CL58.
Document:
1.
99mTc/
188The anti-CEA monoclonal antibody CL58 and the biodistribution research thereof of Re labelling, Chinese Journal of Nuclear Medicine, Vol 20, No5:p228-229 (2000);
2.CHARACTERIZATION?OF?MONOCLONAL?ANTIBODY?CL58AGAINST?CARCINOEMBRYONIC?ANTIGEN?(CEA)?AND?STUDYOF?ITS?BIODISTRIBUTION。Chinese?Journal?of?CancerResearch，2002，Vol.14(2)：p108-112；
3. people's colorectal cancer mucosa research of the anti-CEA monoclonal antibody of injection-(125) I labelling CL58 radioimmunoguided surgery system down, Chinese general surgery magazine, 2002, Vol 7, No.10:p599-601;
4.Clinical?Application?of?Radioimmunoguided?Surgery?inColorectal?Cancer?Using?125I-LabeledCarcinoembryonic?Antigen-Specific?MonoclonalAntibody?Submucosally.Diseases?of?the?Colon?&?Rectum.46(12)：1659-1666，December?2003.
Claims (6)
1, a kind of radiative immune guiding operating medicine of colorectal disease is characterized in that, described medicine is to be made after labelling, lyophilizing by CL58 antibody.
2, the preparation method of medicine according to claim 1 is characterized in that this method may further comprise the steps:
(1) radioactive labelling: in CL58 antibody, add the buffer solution adjust pH to 7-8, after shaking up, add Na
125I solution adds N-bromosuccinimide again, shakes up, and fully after the reaction, adds human serum albumin's cessation reaction, and obtains antibody behind the labelling purification with the PD-10 column purification;
(2) lyophilizing of traget antibody: get the antibody behind the labelling purification, add protective agent, forming agent or polysaccharide postlyophilization and get final product.
3, preparation method as claimed in claim 2 is characterized in that, described buffer solution is phosphate buffer.
4, preparation method as claimed in claim 2 is characterized in that, described protective agent is selected from following material: human serum albumin, V
C, human IgG and other irrelevant protein.
5, preparation method as claimed in claim 2 is characterized in that, described forming agent is selected from following material: carbamide, sucrose, fructose.
6, preparation method as claimed in claim 2 is characterized in that, described polysaccharide is selected from one or more in the following material: mannitol, sucrose, fructose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100112775A CN1313161C (en) | 2005-01-27 | 2005-01-27 | Preparation of radiative immune guiding operating medicine of colorectal disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100112775A CN1313161C (en) | 2005-01-27 | 2005-01-27 | Preparation of radiative immune guiding operating medicine of colorectal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679970A true CN1679970A (en) | 2005-10-12 |
| CN1313161C CN1313161C (en) | 2007-05-02 |
Family
ID=35066957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100112775A Expired - Fee Related CN1313161C (en) | 2005-01-27 | 2005-01-27 | Preparation of radiative immune guiding operating medicine of colorectal disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1313161C (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| EP0852951A1 (en) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals |
-
2005
- 2005-01-27 CN CNB2005100112775A patent/CN1313161C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1313161C (en) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stickney et al. | Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma | |
| DeLand et al. | Imaging approach in radioimmunodetection | |
| CA2100256C (en) | A method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion,and the use of said agents for said purpose | |
| Wahl et al. | Improved radioimaging and tumor localization with monoclonal F (ab′) 2 | |
| Rossin et al. | Diels–Alder reaction for tumor pretargeting: in vivo chemistry can boost tumor radiation dose compared with directly labeled antibody | |
| Order et al. | Use of isotopic immunoglobulin in therapy | |
| Levchenko et al. | Evaluation of 11C-colchicine for PET imaging of multiple drug resistance | |
| Saga et al. | Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin | |
| Neuwelt et al. | Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system | |
| JPH03500419A (en) | Multispecific anti-leukocyte conjugate and parenteral injection for mammals | |
| KR20040068363A (en) | Labeling Targeting Agents with Gallium-68 and Gallium-67 | |
| Munz et al. | Improved radioimmunoimaging of human tumor xenografts by a mixture of monoclonal antibody F (ab′) 2 fragments | |
| Khawli et al. | Improved tumor localization and radioimaging with chemically modified monoclonal antibodies | |
| Palm et al. | Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer | |
| Byers et al. | Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents | |
| Gold et al. | Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4 | |
| Hnatowich et al. | Improved tumor localization with (strept) avidin and labeled biotin as a substitute for antibody | |
| Smellie et al. | Radioimmunotherapy of Breast Cancer Xenografts with Monoclonal Antibody ICR12 against c-erb B2 p185: Comparison of Iodogen and N-Succinimidyl 4-Methyl-3-(tri-n-butylstannyl) benzoate Radioiodination Methods | |
| Fritzberg et al. | Approaches to improved antibody-and peptide-mediated targeting for imaging and therapy of cancer | |
| Thakur et al. | Technetium-99m-labeled monoclonal antibodies for immunoscintigraphy: simplified preparation and evaluation | |
| CN1313161C (en) | Preparation of radiative immune guiding operating medicine of colorectal disease | |
| Alauddin et al. | An improved method of direct labeling monoclonal antibodies with 99mTc | |
| Griffin et al. | Intraperitoneal immunoconjugates | |
| Britton et al. | Radiolabelled monoclonal antibodies in oncology I. Technical aspects | |
| McQuarrie et al. | The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070502 Termination date: 20140127 |